{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:07Z","timestamp":1786119307140,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1097\/mbc.0b013e328304e00d","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T13:52:31Z","timestamp":1236261151000},"page":"401-404","source":"Crossref","is-referenced-by-count":8,"title":["What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention?"],"prefix":"10.1097","volume":"19","author":[{"given":"Ignacio","family":"Cruz-Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sanchez-Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Osakabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikari","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne J","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine L","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ik-Kyung","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210203","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1161\/CIRCULATIONAHA.104.518563","article-title":"When heparins promote thrombosis: review of heparin-induced thrombocytopenia","volume":"111","author":"Jang","year":"2005","journal-title":"Circulation"},{"key":"R2-11-20210203","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-0038-1648875","article-title":"Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin","volume":"72","author":"Berry","year":"1994","journal-title":"Thromb Haemost"},{"key":"R3-11-20210203","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ccd.10276","article-title":"Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia","volume":"57","author":"Lewis","year":"2002","journal-title":"Catheter Cardiovasc Interv"},{"key":"R4-11-20210203","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0735-1097(00)00804-4","article-title":"Myocardial infarction redefined\u2013 a consensus document of The Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction","volume":"36","author":"Alpert","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R5-11-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial\u2013 phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"R6-11-20210203","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood.V96.5.1703","article-title":"Impact of the patient population on the risk for heparin-induced thrombocytopenia","volume":"96","author":"Warkentin","year":"2000","journal-title":"Blood"},{"key":"R7-11-20210203","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/archinte.163.20.2518","article-title":"An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients","volume":"163","author":"Warkentin","year":"2003","journal-title":"Arch Intern Med"},{"key":"R8-11-20210203","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A 14-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med"},{"key":"R9-11-20210203","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0735-1097(98)00134-X","article-title":"Heparin-induced thrombocytopenia","volume":"31","author":"Brieger","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"R10-11-20210203","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-0037-1615866","article-title":"Treatment of heparin-induced thrombocytopenia","volume":"82","author":"Greinacher","year":"1999","journal-title":"Thromb Haemost"},{"key":"R11-11-20210203","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.ahj.2005.09.002","article-title":"Argatroban: update","volume":"151","author":"Yeh","year":"2006","journal-title":"Am Heart J"},{"key":"R12-11-20210203","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1592\/phco.26.4.461","article-title":"Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia","volume":"26","author":"Dang","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"5 Suppl","key":"R13-11-20210203","doi-asserted-by":"crossref","first-page":"489S","DOI":"10.1378\/chest.114.5_Supplement.489S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety","volume":"114","author":"Hirsh","year":"1998","journal-title":"Chest"},{"key":"R14-11-20210203","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11239-004-0171-2","article-title":"Argatroban anticoagulation in conjunction with glycoprotein IIb\/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study","volume":"18","author":"Jang","year":"2004","journal-title":"J Thromb Thrombolysis"},{"key":"R15-11-20210203","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s11239-007-0071-3","article-title":"Efficacy and safety of Argatroban with or without glycoprotien IIb\/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome","volume":"25","author":"Cruz-Gonzalez","year":"2008","journal-title":"J Thromb Thrombolysis"},{"key":"R16-11-20210203","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1067\/mhj.2003.43","article-title":"Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry","volume":"145","author":"Bahit","year":"2003","journal-title":"Am Heart J"}],"container-title":["Blood Coagulation & Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001721-200807000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:56:28Z","timestamp":1786038988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001721-200807000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0b013e328304e00d","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}